Literature DB >> 9246677

Antisense strategies in neurobiology.

B Weiss1, G Davidkova, S P Zhang.   

Abstract

The use of antisense oligodeoxynucleotides, targeted to the transcripts encoding biologically active proteins in the nervous system, provides a novel and highly selective means to further our understanding of the function of these proteins. Recent studies of these agents also suggest the possibility of their being used therapeutically for a variety of diseases involving neuronal tissue. In this paper we review studies showing the in vitro and in vivo effects of antisense oligodeoxynucleotides as they relate to neurobiological functions. Particular attention is paid to the behavioral and biochemical effects of antisense oligodeoxynucleotides directed to the various subtypes of receptors for the neurotransmitter dopamine. An example is also provided showing the effects of a plasmid vector expressing an antisense RNA targeted to the calmodulin mRNAs in the PC12 pheochromocytoma cell line. The advantages of antisense oligodeoxynucleotides over traditional pharmacological treatments are assessed, and the advantages of using vectors encoding antisense RNA over the use of antisense oligodeoxynucleotides are also considered. We also describe the criteria that should be used in designing antisense oligodeoxynucleotides and several controls that should be employed to assure their specificity of action.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9246677     DOI: 10.1016/s0197-0186(96)00105-2

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  8 in total

Review 1.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Knockdown of AMPA receptor GluR2 expression causes delayed neurodegeneration and increases damage by sublethal ischemia in hippocampal CA1 and CA3 neurons.

Authors:  K Oguro; N Oguro; T Kojima; S Y Grooms; A Calderone; X Zheng; M V Bennett; R S Zukin
Journal:  J Neurosci       Date:  1999-11-01       Impact factor: 6.167

3.  Differential involvement of the sigma(1) (sigma(1)) receptor in the anti-amnesic effect of neuroactive steroids, as demonstrated using an in vivo antisense strategy in the mouse.

Authors:  T Maurice; V L Phan; A Urani; I Guillemain
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

4.  Behavioural and physiological effects induced by an infusion of antisense to alpha(2D)-adrenoceptors in the rat.

Authors:  E S Robinson; D J Nutt; H C Jackson; A L Hudson
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

5.  Downregulation of the urokinase-type plasminogen activator receptor through inhibition of translation by antisense oligonucleotide suppresses invasion of human glioblastoma cells.

Authors:  P M Mohan; S S Lakka; S Mohanam; Y Kin; R Sawaya; A P Kyritsis; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

6.  Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum.

Authors:  M Kornmann; N Arber; M Korc
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

7.  Autoradiographical and behavioural effects of a chronic infusion of antisense to the alpha2D-adrenoceptor in the rat.

Authors:  E S Robinson; D J Nutt; L Hall; H C Jackson; A L Hudson
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

8.  Ischemic insults derepress the gene silencer REST in neurons destined to die.

Authors:  Agata Calderone; Teresa Jover; Kyung-min Noh; Hidenobu Tanaka; Hidenori Yokota; Ying Lin; Sonja Y Grooms; Roodland Regis; Michael V L Bennett; R Suzanne Zukin
Journal:  J Neurosci       Date:  2003-03-15       Impact factor: 6.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.